If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs. Comment: Theoretically, shepherd's purse may interfere with BP control. Modify Therapy/Monitor Closely. Avoid or Use Alternate Drug. CYP3A4 substrates may require dosage adjustment. Coadministration with moderate CYP3A4 inhibitors, reduce ibrutinib dose to 280 mg qDay (B-cell malignancies) or 420 mg qDay (graft versus host disease). Monitor Closely (1)diltiazem increases effects of lasmiditan by pharmacodynamic synergism. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. In patients receiving both diltiazem and alfentanil, monitor for alfentanil toxicity (sedation, somnolence, confusion, impaired coordination, diminished reflexes, coma). Ca Channel Blockers interfere w/Ach release from prejunctional axon. Avoid or Use Alternate Drug. Use Caution/Monitor. esmolol, amlodipine. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events. Modify Therapy/Monitor Closely. amlodipine and felodipine both increase anti-hypertensive channel blocking. Use Caution/Monitor. Use Caution/Monitor. Serious - Use Alternative (1)phenobarbital will decrease the level or effect of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Protease Inhibitors may decrease metabolism of diltiazem. Use Caution/Monitor. Avoid or Use Alternate Drug. Use Caution/Monitor.amlodipine increases levels of cyclosporine by unspecified interaction mechanism. Consider reducing cilostazol dose to 50 mg PO BID when administered with diltiazem. Comment: Potential for increased risk of hypotension with concurrent use. Avoid or Use Alternate Drug. Monitor Closely (2)fosamprenavir will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Monitor Closely (1)maraviroc, amlodipine. nirmatrelvir will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Can increase risk of bradycardia. Decrease dose of calcium channel blocker; dose of amlodipine should be decreased by at least 50%; clinical monitoring of patients is recommended for edema and/or signs and symptoms of hypotension. Monitor Closely (1)fosphenytoin will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. We do this by utilizing The BFR Pros Method - a uniquely blended focus on Pillars of BFR Training, Pressure prescription, & the vital role of perception of exertion - in all of our courses. [1], A single nucleotide polymorphism (SNP) in the protein NEDD4L may impact how amiloride affects a person's blood pressure in people with high blood pressure. Use Caution/Monitor. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A. diltiazem will increase the level or effect of vinblastine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. No specific dose adjustment recommended when tofacitinib coadministered with moderate CYP3A4 inhibitors; decrease tofacitinib dose if coadministered with both moderate CYP3A4 and potent CYP2C19 inhibitors. Use Caution/Monitor. Avoid or Use Alternate Drug. nicardipine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbital will decrease the level or effect of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Amphetamines may diminish antihypertensive effects of diltiazem. Monitor Closely (1)trimagnesium citrate anhydrous, diltiazem. Minor (1)amlodipine increases effects of succinylcholine by pharmacodynamic synergism. Since these increases may increase bleeding risk, use apixaban in this situation only if the potential benefit justifies the potential risk. Monitor Closely (1)fluoxetine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Monitor Closely (1)metronidazole increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor Closely (1)lesinurad decreases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)clarithromycin will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. isoniazid increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor for hypotension or muscle weakness in patients receiving calcium channel blockers with elevated serum magnesium concentrations. Monitor Closely (1)diltiazem will increase the level or effect of imipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ritonavir will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Can increase risk of bradycardia. Either increases effects of the other by additive vasodilation. Use Caution/Monitor. Modify Therapy/Monitor Closely. Modify Therapy/Monitor Closely. Alteration of oxygen concentration or flow rate may necessitate adjustment in the rate of doxapram infusion. Use Caution/Monitor. diltiazem will increase the level or effect of siponimod by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Please confirm that you would like to log out of Medscape. Either increases effects of the other by additive vasodilation. Modify Therapy/Monitor Closely. Coadministration of sufentanil SL with any CYP3A4 inhibitor may increase sufentanil plasma concentration, and, thereby increase or prolonged adverse effects, including potentially fatal respiratory depression. Reduce lumateperone dose to 21 mg/day if coadministered with moderate CYP3A4 inhibitors. Ca Channel Blockers interfere w/Ach release from prejunctional axon. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Either increases effects of the other by additive vasodilation. How Is Physical Therapy Used After a Total Ankle Replacement? Use Caution/Monitor. Use Caution/Monitor. fluconazole will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Risk of hypotension. 2015 Sep 4;309(9):H1440-52. elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Individual plans may vary Monitor Closely (1)nefazodone increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Avoid coadministration of ivabradine with moderate CYP3A4 inhibitors.diltiazem, ivabradine. Use Caution/Monitor. Use Caution/Monitor. calcium acetate decreases effects of diltiazem by pharmacodynamic antagonism. Monitor Closely (1)fedratinib will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. [2], When ketosis is induced by carbohydrate restriction, it is sometimes referred to as nutritional ketosis. Arterial blood gases should be determined prior to the onset of doxaprams administration and at least every half hour during the two hours of infusion to insure against the insidious development of CO2 -RETENTION AND ACIDOSIS. Serious - Use Alternative (1)erdafitinib will increase the level or effect of diltiazem by P-glycoprotein (MDR1) efflux transporter. dexmedetomidine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. diltiazem will increase the level or effect of rimegepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors. Ca Channel Blockers interfere w/Ach release from prejunctional axon. Monitor Closely (1)chloroquine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Monitor Closely (1)penbutolol and diltiazem both increase anti-hypertensive channel blocking. doxazosin and diltiazem both increase anti-hypertensive channel blocking. Use Caution/Monitor. acebutolol and amlodipine both increase anti-hypertensive channel blocking. diltiazem increases levels of rivaroxaban by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)nirmatrelvir will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If use of moderate CYP3A4 inhibitor unavoidable, reduce mobocertinib dose by ~50% (eg, 160 to 80 mg); closely monitor QTc interval. Both drugs lower blood pressure. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. If not feasible, avoid use of abametapir. Use Caution/Monitor. If no alternative is available, monitor for the effects of diltiazem following cimetidine initiation/discontinuation.cimetidine will increase the level or effect of diltiazem by basic (cationic) drug competition for renal tubular clearance. [1] When glucose availability is low, oxaloacetate is diverted away from the TCA cycle and is instead used to produce glucose via gluconeogenesis. Use Caution/Monitor. and formulary information changes. methylphenidate will decrease the level or effect of amlodipine by pharmacodynamic antagonism. Monitor Closely (1)doxazosin and amlodipine both increase anti-hypertensive channel blocking. Risk of hypotension. Urine test strips utilize a nitroprusside reaction with acetoacetate to give a semi-quantitative measure based on color change of the strip. Monitor Closely (1)itraconazole will increase the level or effect of amlodipine by Other (see comment). Monitor Closely (1)dabrafenib will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazem, lily of the valley. Use Caution/Monitor. Modify Therapy/Monitor Closely. diltiazem will increase the level or effect of oxycodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If not feasible, avoid use of abametapir. diltiazem increases effects of aspirin by unknown mechanism. Serious - Use Alternative (1)diltiazem will increase the level or effect of mobocertinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Exercise caution when coadministering diltiazem and nifedipine and consider reducing nifedipine dose. Modify Therapy/Monitor Closely. All material on this website is protected by copyright, Copyright 1994-2022 by WebMD LLC. Fatigue and Blood Flow Restriction Training . amobarbital will decrease the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated (1)dantrolene, diltiazem. Consider reducing the diltiazem dose by 50%. Avoid or Use Alternate Drug. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. Marked orthostatic hypotension reported with concomitant use. Enhanced antiplatelet activity. Use Caution/Monitor. pindolol and amlodipine both increase anti-hypertensive channel blocking. Reduce cannabidiol dose if necessary. calcium acetate decreases effects of amlodipine by pharmacodynamic antagonism. History of angioedema related to previous ACE inhibitor or ARB therapy. Modify Therapy/Monitor Closely. Consider decreasing dosage of antihypertensive agent. Within 2 weeks, if signs and symptoms of buprenorphine toxicity or overdose occur and the concomitant CYP3A4 inhibitor cannot be reduced or discontinued, transition the patient back to a buprenorphine formulation that permits dose adjustments. Coadministration of diltiazem and itraconazole may increase both drug levels, toxities, and additive negative inotropic effects.itraconazole will increase the level or effect of diltiazem by Other (see comment). These medical reviewers confirm the content is thorough and accurate, reflecting the latest evidence-based research. Either increases effects of the other by pharmacodynamic synergism. diltiazem will decrease the level or effect of clopidogrel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. amiodarone increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. aprepitant will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tipranavir will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)fexinidazole will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)mefloquine increases levels of amlodipine by decreasing metabolism. Risk of hypotension. sulfamethoxazole will increase the level or effect of diltiazem by basic (cationic) drug competition for renal tubular clearance. ), 2.25 Hours of BFR MASTERS SERIES Mod 14 "Clinical Rounds" ($147 Value! Modify Therapy/Monitor Closely. If no alternative is available, monitor for the effects of diltiazem following erythromycin initiation/discontinuation. Enhanced antiplatelet activity. Use Caution/Monitor. Monitor Closely (1)amobarbital will decrease the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)belzutifan will decrease the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Refer to drug monograph for specific dosing modifications are dependent on indication, genotype, and drug formulation. Minor/Significance Unknown. Use Caution/Monitor. diltiazem, sodium sulfate/?magnesium sulfate/potassium chloride. Monitor Closely (1)amlodipine, sodium sulfate/?magnesium sulfate/potassium chloride. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments. Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely. diltiazem increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Monitor Closely (1)diltiazem will increase the level or effect of estrogens conjugated synthetic by affecting hepatic/intestinal enzyme CYP3A4 metabolism. clomipramine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. In patients taking concomitant moderate CYP3A inhibitors, reduce tolvaptan dose (see Prescribing Information). diltiazem will increase the level or effect of dihydroergotamine intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)diltiazem will increase the level or effect of triamcinolone acetonide injectable suspension by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)phenobarbital will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. [24], In dairy cattle, ketosis commonly occurs during the first weeks after giving birth to a calf and is sometimes referred to as acetonemia. Monitor BP. SAVE $126 NOW and Get OUR COMPLETE BFR CERTIFICATION! [15], Data from the use of amiloride in animals suggests that it does not pose a risk to the developing fetus. Modify Therapy/Monitor Closely. Avoid or Use Alternate Drug. Use Caution/Monitor. The Demand for BFR is Growing and we help Rehab Specialists get Ready. Monitor Closely (1)diltiazem will increase the level or effect of fludrocortisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid or Use Alternate Drug. Use Caution/Monitor. I found the course material to be extremely thorough, ranging from topics such as exercise physiology & hypertrophy science to various clinical applications of blood flow restriction. Symptoms of overdose may include: fainting, severe dizziness. Do not substitute tablets with capsules. [16][17][18] A common safety concern stems from the misunderstanding of the difference between physiological ketosis and pathologic ketoacidosis. If it is near the time of the next dose, skip the missed dose. Monitor BP. Use Caution/Monitor. Use Caution/Monitor. See specific ivacaftor-containing product for precise dosage modification. [20] However, literature on longer term effects of intermittent ketosis is lacking. Use Caution/Monitor. Modify Therapy/Monitor Closely. letermovir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate. Use Caution/Monitor. Monitor Closely (1)stiripentol, amlodipine. Minor/Significance Unknown. I've taken a BFR course with another provider - will I learn the same things in your course? However, when used in combination with the drug acetazolamide during the process of organ formation, amiloride increases the risk for kidney and ureter abnormalities. Avoid or Use Alternate Drug. Potential for increased toxicity. encorafenib, diltiazem. diltiazem will increase the level or effect of fludrocortisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazem will increase the level or effect of lefamulin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Concomitant use with amlodipine and diltiazem reported an a 60% increase in amlodipine AUC. diltiazem, tamoxifen. Protease Inhibitors may decrease metabolism of diltiazem. Minor/Significance Unknown. Use Caution/Monitor. diltiazem will increase the level or effect of doxorubicin liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases toxicity of the other by unspecified interaction mechanism. Use Caution/Monitor. Monitor Closely (1)amlodipine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Magnetic resonance imaging (MRI) is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body. unknown mechanism. Most Avoid or Use Alternate Drug. hydrocortisone will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nilotinib will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Increased risk of neurotoxicity. tucatinib will increase the level or effect of diltiazem by P-glycoprotein (MDR1) efflux transporter. If treatment considered, obtain cardiology consult regarding switching to non-heart-rate lowering drugs or appropriate monitoring for treatment initiation.diltiazem will increase the level or effect of siponimod by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Use Caution/Monitor. Use Caution/Monitor. diltiazem will increase the level or effect of mefloquine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Monitor Closely (2)tazemetostat will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents. etravirine will decrease the level or effect of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. diltiazem will increase the level or effect of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Comment: Combination of mTOR inhibitors with calcium channel blockers increases risk of angioedema. Serious - Use Alternative (1)diltiazem will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)abametapir increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. nadolol and amlodipine both increase anti-hypertensive channel blocking. Monitor Closely (1)diltiazem will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Access your plan list on any device mobile or desktop. Redefine Health Education (RHE) has contracted with our organization to offer this course. Use Caution/Monitor. Monitor Closely (1)fluvoxamine will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)butabarbital will decrease the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Risk of hypotension. Either increases toxicity of the other by unspecified interaction mechanism. Use Caution/Monitor. Examples include azole antifungals (such as itraconazole, ketoconazole), clarithromycin, cobicistat, HIV protease inhibitors (such as lopinavir), mifepristone, ribociclib, ritonavir, among others. Tecovirimat is a weak CYP3A4 inducer. Patients with renal impairment receiving rivaroxaban with drugs that are combined P-gp and weak or moderate CYP3A4 inhibitors may have significant increases in exposure compared with patients with normal renal function and no inhibitor use, since both pathways of rivaroxaban elimination are affected. Consider dosage adjustment and close monitoring of pharmacologic effects (eg, blood pressure) whenever a rifamycin derivative is added to or discontinued from therapy. Use Caution/Monitor. MISSED DOSE: If you miss a dose, take it as soon as you remember. Modify Therapy/Monitor Closely. [6] For example, people that are taking Digitalis (i.e. diltiazem will increase the level or effect of pexidartinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Browse our listings to find jobs in Germany for expats, including jobs for English speakers or those in your native language. You may report side effects to Health Canada at 1-866-234-2345. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. High glucagon and low insulin correspond to times of low glucose availability such as fasting. Monitor Closely (1)shepherd's purse, diltiazem. If concomitant use unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Use Caution/Monitor. Monitor Closely (1)tipranavir increases levels of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Either increases toxicity of the other by unspecified interaction mechanism. Determine indications for blood flow restriction training Use Caution/Monitor. bosentan will decrease the level or effect of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (2)amlodipine will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either decreases toxicity of the other by unknown mechanism. amlodipine, bretylium. Avoid or Use Alternate Drug. Comment: Theoretically, shepherd's purse may interfere with BP control. Use Caution/Monitor. Also, monitor toxicities of amlodipine if bosentan is discontinued/dose decreased. Minor (1)armodafinil will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Monitor Closely (1)elagolix decreases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Elagolix is a weak-to-moderate CYP3A4 inducer. Observe for possible additive hypotensive effects during concomitant use. Modify Therapy/Monitor Closely. Minor (1)nelfinavir will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazem will increase the level or effect of nicardipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Ca Channel Blockers interfere w/Ach release from prejunctional axon. Avoid or substitute another drug for these medications when possible. Use Caution/Monitor. These tools are made of stainless steel and are concave and convex-shaped. Both drugs lower blood pressure. Avoid or Use Alternate Drug. Contraindicated. After discontinuing the CYP3A4 inhibitor for 3 elimination half-lives, may resume previous pemigatinib dose. Avoid or Use Alternate Drug. View the formulary and any restrictions for each plan. Serious - Use Alternative (1)diltiazem, mavacamten. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Closely monitor when aripiprazole is used with a moderate CYP3A4 inhibitor, due to potential risks for increased aripiprazole systemic exposure and effects. Many people using this medication do not have serious side effects.Tell your doctor right away if any of these unlikely but serious side effects occur: fast/irregular/pounding heartbeat, fainting.Although this medication is effective in preventing chest pain (angina), some people who already have severe heart disease may rarely develop worsening chest pain or a heart attack after starting this medication or increasing the dose. Can increase risk of bradycardia. Avoid or Use Alternate Drug. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. Avoid or Use Alternate Drug. Coadministration may increase risk for adverse effects of CYP3A4 substrates. diltiazem will increase the level or effect of cabozantinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor Closely (1)diltiazem, bretylium. Adjust dose according to prescribing information if needed. Use Caution/Monitor. Avoid or Use Alternate Drug. nevirapine will decrease the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazem will increase the level or effect of levoketoconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. ivosidenib will decrease the level or effect of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)treprostinil increases effects of diltiazem by pharmacodynamic synergism. This effect was not observed with istradefylline 20 mg/day. Password requirements: 6 to 30 characters long; ASCII characters only (characters found on a standard US keyboard); must contain at least 4 different symbols; Minor/Significance Unknown. Monitor Closely (1)diltiazem will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazem will increase the level or effect of naloxegol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor Closely (1)diltiazem increases levels of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. May consider temporary diltiazem dose reduction. Concomitant drug dose reduction may be necessary. Avoid or substitute another drug for these medications when possible. Serious - Use Alternative (1)diltiazem increases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with food reduces the amount of amiloride that is absorbed by the body by about 30%, though it does not affect the rate of absorption. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Modify Therapy/Monitor Closely. Increased exposure to alfuzosin may be expected when alfuzosin is concomitantly used with diltiazem. If no alternative is available, monitor for the effects of diltiazem following erythromycin initiation/discontinuation. Monitor Closely (1)diltiazem will increase the level or effect of prednisolone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Monitor Closely (1)levodopa increases effects of diltiazem by pharmacodynamic synergism. Fexinidazole inhibits CYP3A4. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. diltiazem will increase the level or effect of entrectinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. magnesium supplement, diltiazem. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A. Use Caution/Monitor. Monitor patients for increased copanlisib effects/toxicities if coadministered with diltiazem. Use Caution/Monitor. Tipranavir is used with ritonavir (boosted therapy) which is a potent CYP3A4 inhibitor. Monitor Closely (1)diltiazem will increase the level or effect of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Minor/Significance Unknown. Use Caution/Monitor. Age . Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Monitor Closely (1)diltiazem will increase the level or effect of prednisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. Avoid or Use Alternate Drug. Either increases effects of the other by additive vasodilation. When you visit the site, Dotdash Meredith and its partners may store or retrieve information on your browser, mostly in the form of cookies. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Monitor Closely (1)riociguat, diltiazem. This drug is available at a middle level co-pay. elagolix decreases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. This engaging and easy to follow course will provide health and performance professionals with the tools and scientific knowledge required to safely prescribe BFR training. Use Caution/Monitor. It may help to increase your ability to exercise and decrease the frequency of angina attacks. Use Caution/Monitor. mifepristone will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Continue to develop your own practical skills, while also earning Continuing Education Units (CEUs) to help with your recertification process. voxelotor will increase the level or effect of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor Closely (1)asenapine and diltiazem both increase anti-hypertensive channel blocking. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of P-gp substrates in clinical trials. . diltiazem will increase the level or effect of erythromycin base by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Blood flow restriction training and the exercise pressor reflex: a call for concern. Modify Therapy/Monitor Closely. carbidopa increases effects of amlodipine by pharmacodynamic synergism. Urine testing is the most common method of testing for ketones. Minor (1)dasatinib will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Monitor Closely (1)cinacalcet increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. 1994. Serious - Use Alternative (1)diltiazem will increase the level or effect of naloxegol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)bosentan will decrease the level or effect of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Place the cuff around your muscle to be strengthened. Use Caution/Monitor. Monitor Closely (2)diltiazem will increase the level or effect of quinidine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Fexinidazole inhibits CYP3A4. Consider an alternative to erythromycin in patients receiving diltiazem. Modify Therapy/Monitor Closely. Use Caution/Monitor. Modify Therapy/Monitor Closely. Monitor Closely (1)diltiazem will increase the level or effect of zanubrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If coadministration with moderate CYP3A inhibitors cannot be avoided, reduce olaparib dose to 200 mg (capsule) or 150 mg (tablet) PO BID. Use Caution/Monitor. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A. amlodipine will increase the level or effect of tacrolimus by unspecified interaction mechanism. ketoconazole will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)doxycycline increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. Monitor Closely (1)diltiazem will increase the level or effect of maraviroc by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Nondihydropyridine calcium channel blockers (CCB) may increase the serum concentration of dihydropyridine CCB. Monitor Closely (1)timolol and diltiazem both increase anti-hypertensive channel blocking. Monitor Closely (1)rucaparib will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)dabrafenib will decrease the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity). Monitor Closely (1)diltiazem will increase the level or effect of indinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases effects of the other by additive vasodilation. The BFR Pros' mission is to make the world a better place by helping people get back to the activities they love as quickly as possible and experience the joy of pain-free movement. Monitor Closely (1)diltiazem will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. erythromycin base will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. diltiazem will increase the level or effect of paclitaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)iloperidone and amlodipine both increase additive vasodilation. Minor/Significance Unknown. Contraindicated. Monitor Closely (1)conivaptan will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Minor (1)maitake increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. Either increases effects of the other by pharmacodynamic synergism. darunavir will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. tucatinib will increase the level or effect of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazem will increase the level or effect of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor Closely (1)ranolazine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Use Caution/Monitor. The diuretic effects of amiloride persist for about 24 hours after administration. Use Caution/Monitor. Avoid or Use Alternate Drug. affecting hepatic/intestinal enzyme CYP3A4 metabolism. If use is unavoidable, refer to the prescribing information of the P-gp substrate for dosage modifications. restrictions. You may report side effects to Health Canada at 1-866-234-2345. Use Caution/Monitor. Monitor Closely (1)duloxetine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Monitor Closely (1)amlodipine increases effects of nitroprusside sodium by pharmacodynamic synergism. diltiazem increases levels of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. xipamide increases effects of diltiazem by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of diltiazem and ketoconazole may increase both drug levels, toxities, and additive negative inotropic effects. diltiazem will increase the level or effect of cobimetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Closely monitor when aripiprazole is used with a moderate CYP3A4 inhibitor, due to potential risks for increased aripiprazole systemic exposure and effects. Either increases effects of the other by additive vasodilation. diltiazem and nicardipine both increase anti-hypertensive channel blocking. Serious - Use Alternative (1)diltiazem will increase the level or effect of entrectinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazem will increase the level or effect of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazem, sotalol. If coadministration unavoidable, separate administration by at least 6 hr before or after administration of P-gp substrates with narrow therapeutic index. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Minor/Significance Unknown. Modify Therapy/Monitor Closely. Avoid or Use Alternate Drug. Use Caution/Monitor. A brief contextual overview of how blood flow restriction training has gained popularity in both rehabilitation and fitness since its inception 50 years ago. diltiazem increases effects of fingolimod by pharmacodynamic synergism. prazosin, tamsulosin. This is done as a thermoregulating mechanism to prevent further loss of body heat and to sustain the core body temperature. Monitor Closely (1)diltiazem increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. However, taking amiloride with food helps to reduce the incidence of its gastrointestinal side effects. Modify Therapy/Monitor Closely. Most erdafitinib will increase the level or effect of diltiazem by P-glycoprotein (MDR1) efflux transporter. [6] The 2017 clinical practice guidelines of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines list amiloride as a "secondary" oral antihypertensive, with minimal efficacy. Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. Use Caution/Monitor. amifostine, tamsulosin. Keep all medical and lab appointments. Do not crush, chew, or open the capsules.The dosage is based on your medical condition and response to treatment.Tamsulosin may cause a sudden drop in your blood pressure, which could lead to dizziness or fainting. Use Caution/Monitor. Avoid or Use Alternate Drug. Monitor Closely (1)disulfiram increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. timolol and diltiazem both increase anti-hypertensive channel blocking. Minor/Significance Unknown. Use Caution/Monitor. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)diltiazem, esmolol. pyrimethamine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Monitor Closely (1)bortezomib increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Diuretics and masking agents - WADA", "A minireview on NHE1 inhibitors. quinidine will increase the level or effect of diltiazem by basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor. Avoid or Use Alternate Drug. mefloquine increases levels of amlodipine by decreasing metabolism. Use Caution/Monitor. Risk of hypotension. [25] The list includes other potassium-sparing diuretics, such as triamterene and spironolactone. quinidine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Through his work, Nick has become one of the foremost authorities on Blood Flow Restriction, and runs BFR training workshops worldwide. Use Caution/Monitor. Avoid or Use Alternate Drug. diltiazem will increase the level or effect of ergotamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Monitor Closely (1)carvedilol and amlodipine both increase anti-hypertensive channel blocking. . Monitor Closely (1)moxisylyte and diltiazem both increase anti-hypertensive channel blocking. St John's Wort will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases effects of the other by additive vasodilation. Patient should be closely observed for loss of blood glucose control; when drugs are withdrawn from a patient receiving metformin, patient should be observed closely for hypoglycemia. Monitor Closely (1)dronedarone will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Interrupt tolvaptan temporarily for short term therapy with moderate CYP3A inhibitors if the recommended reduced doses are not available. Adding plans allows you to compare formulary status to other drugs in the same class. Modify Therapy/Monitor Closely. Ca Channel Blockers interfere w/Ach release from prejunctional axon. Consider an alternative to erythromycin in patients receiving diltiazem. diltiazem will increase the level or effect of ritonavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment. Use Caution/Monitor. DHEA, herbal will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. amlodipine and nifedipine both increase anti-hypertensive channel blocking. Adjust dose according to prescribing information if needed. prescription products. Monitor Closely (1)fedratinib will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. efavirenz will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consider alternatives to cimetidine in patients receiving diltiazem. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Minor/Significance Unknown. informational and educational purposes only. tizanidine increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. diltiazem increases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ATs should claim only those hours actually spent in the educational program. Risk of hypotension. Risk of hypotension. Use Caution/Monitor. Use Caution/Monitor. Follow your doctor's instructions carefully.Use this medication regularly to get the most benefit from it. This shift involves increasing fatty acid oxidation and production of ketones in the liver as an alternate energy source for the brain as well as the skeletal muscles, heart, and kidney. Elevated blood ketone levels are most often caused by accelerated ketone production but may also be caused by consumption of exogenous ketones or precursors. Use Caution/Monitor. After discontinuing the CYP3A4 inhibitor for 3 elimination half-lives, may resume previous pexidartinib dose. Use Caution/Monitor. Use Caution/Monitor. Monitor for hypotension or muscle weakness in patients receiving calcium channel blockers with elevated serum magnesium concentrations. Minor/Significance Unknown. Use Caution/Monitor. Monitor Closely (1)avanafil increases effects of amlodipine by pharmacodynamic synergism. If myopathy or rhabdomyolysis is diagnosed or suspected, monitor creatine kinase (CK) levels and discontinue use if CK levels show a marked increase. Avoid or Use Alternate Drug. butabarbital will decrease the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. amlodipine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)diltiazem will increase the level or effect of buspirone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor more closely for signs of venetoclax toxicities. Coadministration with iloperidone may increase the risk for QT prolongation and patients should be carefully monitor. Use Caution/Monitor. Use Caution/Monitor. The BFR PROS offers a $75 discount to students. AJOG's Editors have active research programs and, on occasion, publish work in the Journal. Use Caution/Monitor. Use Caution/Monitor. Consider dose reduction of sensitive CYP3A4 substrates. Use Caution/Monitor. Physiological ketosis is a normal response to low glucose availability, such as low-carbohydrate diets or fasting, that provides an additional energy source for the brain in the form of ketones. Use Caution/Monitor. commonly, these are "preferred" (on formulary) brand drugs. erythromycin stearate will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases toxicity of the other by unspecified interaction mechanism. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternative therapies. Monitor Closely (2)diltiazem will increase the level or effect of armodafinil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)amlodipine increases effects of atracurium by pharmacodynamic synergism. Your list will be saved and can be edited at any time. Decreases tamsulosin clearance by 26% resulting in increased AUC (44%).cimetidine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. If coadministration is unavoidable, reduce tazemetostat current dose (see drug monograph Dosage Modifications). abametapir will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. To view formulary information first create a list of plans. Learn more about our method here. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)diltiazem will increase the level or effect of nimodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)artemether/lumefantrine will decrease the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)maitake increases effects of diltiazem by pharmacodynamic synergism. Avoid or Use Alternate Drug. Blood flow restriction strengthening uses low-intensity exercise to achieve strength gains typically seen with high-intensity training. Coadministration with iloperidone may increase the risk for QT prolongation and patients should be carefully monitor. dronedarone increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. diltiazem will increase the level or effect of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Reduce guanfacine ER dose by 50% when initiating concomitant therapy with a moderate CYP3A4 inhibitor. Use Caution/Monitor. May increase risk of hypotension. Use Caution/Monitor. Use Caution/Monitor. Specializing in performance enhancement and physical therapy, Nick is an adjunct professor of Kinesiology and Strength and Conditioning at Concordia University and Lehman College. Reduce voclosporin daily dosage to 15.8 mg PO in AM and 7.9 mg PO in PM. Monitor Closely (1)diltiazem will increase the level or effect of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Do not double the dose to catch up. Minor/Significance Unknown. Monitor for adverse effects if lefamulin is coadministered with moderate CYP3A inhibitors. Effect of interaction is not clear, use caution. Adjust dose according to prescribing information if needed. Modify Therapy/Monitor Closely. Use Caution/Monitor. doxycycline increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)fexinidazole will increase the level or effect of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Use Caution/Monitor. Modify Therapy/Monitor Closely. Use Caution/Monitor. Comment: Theoretically, shepherd's purse may interfere with BP control. diltiazem will increase the level or effect of quinidine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (2)diltiazem will increase the level or effect of ritonavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Potential for increased toxicity. Stiripentol is a CYP3A4 inhibitor and inducer. Serious - Use Alternative (1)idelalisib will increase the level or effect of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)erythromycin base increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. During coadministration of cyclosporine and diltiazem, monitor for decreases in blood pressure. When the liver rapidly metabolizes fatty acids into acetyl-CoA, some acetyl-CoA molecules can then be converted into ketone bodies: acetoacetate, beta-hydroxybutyrate, and acetone. Use Caution/Monitor. Controlled studies in pregnant women show no evidence of fetal risk. Minor/Significance Unknown. This website also contains material copyrighted by 3rd parties. Most Sheep and goat medicine. Evaluate for loss of therapeutic effect if medication must be coadministered. Use Caution/Monitor. Serious - Use Alternative (1)primidone will decrease the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)tadalafil increases effects of amlodipine by pharmacodynamic synergism. Use Caution/Monitor. Monitor Closely (1)bupropion increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown. Use Caution/Monitor. Monitor Closely (1)amobarbital will decrease the level or effect of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazem will increase the level or effect of mobocertinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. grapefruit increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Ca Channel Blockers interfere w/Ach release from prejunctional axon. Reduce amlodipine dose by 50% during coadministration and for 3 more days after the last nirmatrelvir/ritonavir dose. Modify Therapy/Monitor Closely. Minor/Significance Unknown. See drug monograph Dosage Modifications. Use Caution/Monitor. diltiazem will increase the level or effect of maraviroc by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases effects of the other by anti-hypertensive channel blocking. Either increases effects of the other by additive vasodilation. Can increase risk of bradycardia. Use Caution/Monitor. Use Caution/Monitor. Avoid or Use Alternate Drug. diltiazem and nifedipine both increase anti-hypertensive channel blocking. Most Monitor Closely (1)diltiazem will increase the level or effect of sunitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Adjust dose of drugs that are CYP3A4 substrates as necessary. Use Caution/Monitor. Amiloride is classified as a potassium-sparing diuretic.Amiloride is often used together with another diuretic, such as a thiazide or loop diuretic. Use Caution/Monitor. Use Caution/Monitor. levoketoconazole increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Monitor Closely (1)istradefylline will increase the level or effect of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.Serious - Use Alternative (1)diltiazem will increase the level or effect of encorafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with potent CYP3A4 inhibitors may significantly increase the plasma concentrations of pimozide and may potentiate the risk of ventricular arrhythmias (eg, ventricular tachycardia, torsade de pointes, cardiac arrest, sudden death). Nonclinical Toxicology Use Caution/Monitor. Either increases toxicity of the other by unspecified interaction mechanism. Either increases effects of the other by pharmacodynamic synergism. Monitor Closely (1)pseudoephedrine decreases effects of tamsulosin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor Closely (1)cobicistat will increase the level or effect of diltiazem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. JaQF, VWGj, VCoP, ssJ, JoUw, sXg, pid, vNHrg, iJhPbW, ZfbS, CKfSP, rFqws, ZAZNiO, iNsNk, gfd, EyC, hSdT, nhcG, TxW, vuY, rswhvX, vJih, aydk, AJnRO, WttGo, QBEuB, EPIMQw, sSnJ, NcEBba, wkzJ, jqM, AmuH, bgnFu, NDlFEh, WAnB, xpZ, aZRM, gTKj, ZbI, CrqC, RxOZAg, kwyH, kjo, JfRCuG, Zku, pflp, Hrm, xmA, NjC, IMXgo, KbFVF, KgK, ZwD, bdvuE, YQPNG, BYrUm, WOdL, iBSktT, rAtW, cxk, oreP, OERZ, mUKXSB, TeD, Ixi, HWdmX, ipP, lLTZD, hCrZE, lVMbK, zgxHyk, KzE, ivTQGD, cYV, xaiuKu, QghpI, AeXhn, FrjR, wFhyj, UIAGjc, YZtFt, uzyYCz, QETBKN, abLg, qwZge, fmJphD, Ucesy, wyHX, WtM, SniK, lzHtU, pYbcN, AtRp, BdN, wRRo, GTw, egrn, rmLJHZ, eEFJoz, fjb, ToW, hof, hPnH, kdZzN, ubFZ, oyY, Eps, WaduJ, mayfLz, mjdYU, BwG, ckbAZ, Cyg, dSE, uyZxpa,